<table className="table"><caption><p>IDSA/ATS Recommendations for Empiric Antibiotics in Community-Acquired Pneumonia</p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Site of Treatment</p></th><th colSpan="1" rowSpan="1"><p>Patient or Epidemiologic Considerations</p></th><th colSpan="1" rowSpan="1"><p>Most Common Organisms</p></th><th colSpan="1" rowSpan="1"><p>Regimens(s)</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p>Outpatient</p></td><td colSpan="1" rowSpan="1"><p>Healthy patient without risk factors for MRSA or <i>Pseudomonas aeruginosa</i></p></td><td colSpan="1" rowSpan="1"><p><i>Streptococcus pneumoniae</i></p><p><i>Mycoplasma</i></p><p><i>Chlamydia</i></p><p><i>Haemophilus influenzae</i></p><p>Respiratory viruses</p></td><td colSpan="1" rowSpan="1"><p>Amoxicillin</p><p>OR</p><p>Doxycycline</p><p>OR</p><p>Macrolide (if local pneumococcal resistance &lt;25%)</p></td></tr><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p></p></td><td colSpan="1" rowSpan="1"><p>Comorbidities<sup>a</sup></p></td><td colSpan="1" rowSpan="1"><p>Same as above</p></td><td colSpan="1" rowSpan="1"><p>Respiratory fluoroquinolone<sup>b</sup></p><p>OR</p><p>Oral β-lactam<sup>c</sup> plus either a macrolide or doxycycline</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p>Inpatient, non-ICU<sup>c</sup></p></td><td colSpan="1" rowSpan="1"><p></p></td><td colSpan="1" rowSpan="1"><p><i>S. pneumoniae</i></p><p><i>Mycoplasma</i></p><p><i>Chlamydia</i></p><p><i>H. influenzae</i></p><p><i>Legionella</i></p><p>Respiratory viruses</p></td><td colSpan="1" rowSpan="1"><p>Intravenous β-lactam<sup>d</sup> plus a macrolide</p><p>OR</p><p>Respiratory fluoroquinolone</p></td></tr><tr className="group_1-3 row-odd"><td colSpan="1" rowSpan="1"><p>ICU treatment</p></td><td colSpan="1" rowSpan="1"><p></p></td><td colSpan="1" rowSpan="1"><p><i>S. pneumoniae</i></p><p><i>Staphylococcus aureus</i></p><p><i>H. influenzae</i></p><p><i>Legionella</i></p><p>Gram-negative bacilli</p></td><td colSpan="1" rowSpan="1"><p>Intravenous β-lactam<sup>d</sup> plus a macrolide; if contraindicated, β-lactam plus respiratory fluoroquinolone is an acceptable alternative</p><p>Consider ancillary glucocorticoids in select patients<sup>e</sup></p></td></tr><tr className="group_1-4 row-even"><td colSpan="1" rowSpan="1"><p>Any</p></td><td colSpan="1" rowSpan="1"><p>Risk factor for <i>Pseudomonas</i> (see text)</p></td><td colSpan="1" rowSpan="1"><p></p></td><td colSpan="1" rowSpan="1"><p>Antipseudomonal β-lactam plus either a macrolide or an antipseudomonal quinolone</p></td></tr><tr className="group_1-5 row-odd"><td colSpan="1" rowSpan="1"><p>Any</p></td><td colSpan="1" rowSpan="1"><p>Risk factor for CA-MRSA (see text)</p></td><td colSpan="1" rowSpan="1"><p></p></td><td colSpan="1" rowSpan="1"><p>Standard therapy PLUS either vancomycin or linezolid</p></td></tr></tbody></table>